D. Scott

发表

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

D. Scott, Andrew R. Bayly, C. Abell, 2016, Nature Reviews Drug Discovery.

Simultaneous determination of gene expression and enzymatic activity in individual bacterial cells in microdroplet compartments.

Wilhelm T S Huck, Graeme Whyte, Luis F. Olguin, 2009, Journal of the American Chemical Society.

Fragment-based approaches in drug discovery and chemical biology.

D. Scott, C. Abell, A. Coyne, 2012, Biochemistry.

Differential Scanning Fluorimetry as Part of a Biophysical Screening Cascade

Chris Abell, Duncan Scott, C. Spry, 2016 .

Using a Fragment-Based Approach To Target Protein–Protein Interactions

T. Blundell, A. Venkitaraman, D. Scott, 2013, Chembiochem : a European journal of chemical biology.

Fragment-based drug discovery in academia: Experiences from a tuberculosis programme

T. Blundell, D. Scott, C. Abell, 2009 .

A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death

T. Blundell, T. Sharpe, G. McKenzie, 2020, bioRxiv.

A Fragment‐Based Approach to Probing Adenosine Recognition Sites by Using Dynamic Combinatorial Chemistry

Chris Abell, Alessio Ciulli, D. Scott, 2009, Chembiochem : a European journal of chemical biology.

ATP half‐sites in RadA and RAD51 recombinases bind nucleotides

T. Blundell, D. Scott, C. Abell, 2016, FEBS open bio.

Drugging challenging targets using fragment-based approaches.

Chris Abell, D. Scott, C. Abell, 2010, Current opinion in chemical biology.

Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode

S. P. Andrews, J. Duce, H. Willems, 2022, Journal of medicinal chemistry.

Coenzyme biosynthesis: enzyme mechanism, structure and inhibition.

D. Scott, C. Abell, A. Ciulli, 2007, Natural product reports.

Structure‐activity relationship of the peptide binding‐motif mediating the BRCA2:RAD51 protein–protein interaction

T. Blundell, D. Scott, C. Abell, 2016, FEBS letters.

Engineering Archeal Surrogate Systems for the Development of Protein–Protein Interaction Inhibitors against Human RAD51

T. Blundell, T. Sharpe, D. Scott, 2016, Journal of molecular biology.

Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases

T. Blundell, A. Venkitaraman, D. Scott, 2014, ChemMedChem.

Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases

T. Blundell, A. Venkitaraman, D. Scott, 2014, ChemMedChem.

Inhibition of Mycobacterium tuberculosis Pantothenate Synthetase by Analogues of the Reaction Intermediate

Chris Abell, Dimitri Y Chirgadze, Tom L Blundell, 2008, Chembiochem : a European journal of chemical biology.

Selective inhibitors of the Aurora A-TPX2 protein-protein interaction exhibit in vivo efficacy as targeted anti-mitotic agents

Alicia P. Higueruelo, T. Blundell, G. McKenzie, 2023, bioRxiv.

The Identification of Potent, Selective, and Brain Penetrant PI5P4Kγ Inhibitors as In Vivo-Ready Tool Molecules

S. P. Andrews, H. Willems, D. Scott, 2022, Journal of medicinal chemistry.

Systematic Investigation of the Permeability of Androgen Receptor PROTACs.

S. P. Andrews, H. Willems, D. Scott, 2020, ACS medicinal chemistry letters.

Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents

Alicia P. Higueruelo, T. Blundell, G. McKenzie, 2024, bioRxiv.